|
|
|
|
DelatestrylGenetic Engineering News, ...(NASDAQ: IDEV) today announced the closing of the previously announced acquisition of the US rights to Delatestryl from Savient Pharmaceuticals, Inc. ... Savient Pharmaceuticals Closes Sale of Delatestryl(R) Product to ... Jan 9, 2006 Genetic Engineering News, ...pharmaceutical products that address unmet medical needs in niche and broader markets, today announced the closing of the sale of its Delatestryl(R) product to ... Savient sells Delatestryl to Indevus Pharmaceuticals for $5m Dec 14, 2005 Globes, Nasdaq: SVNT) has announced that it will sell its injectable testosterone product for male hypogonadism (testosterone deficiency), Delatestryl, to Indevus ... Savient Pharmaceuticals Agrees to Sale of Delatestryl(R) to ... Dec 13, 2005 Genetic Engineering News, ...for unmet medical needs, announced today that the Company has agreed to sell its injectable testosterone product for male hypogonadism, Delatestryl(R), to ... Indevus Pharmaceuticals Announces Fiscal 2005 Year End and Fourth ... Dec 13, 2005 Business Wire (press release), Additionally, the Company announced today that it has reached a definitive agreement to acquire Delatestryl (testosterone enanthate) from Savient ... Indevus says to acquire testosterone drug from Savient Dec 13, 2005 Reuters Pharmaceuticals Inc. (IDEV.O: Quote, Profile, Research) said on Tuesday it would acquire Delatestryl from Savient Pharmaceuticals Inc. (SVNTE ... Indevus fourth-quarter loss narrows Dec 13, 2005 BusinessWeek Separately, the company also said it agreed to buy an injectable medication, Delatestryl, for a male testosterone disorder from Savient Pharmaceuticals Inc. ... Savient Eliminates a Product Dec 13, 2005 Business New Jersey (subscription), Brunswick-based Savient Pharmaceuticals (NASDAQ: SVNTE) has agreed to sell its injectable treatment for male testosterone deficiency, Delatestryl, to Indevus ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |